@article{23cdb9f8501a4134aa6b20267e4b5894,
title = "What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?",
keywords = "castration-resistant prostate cancer, neoplasm metastasis, neoplasm recurrence, oligometastasis, prostate cancer, stereotactic ablative radiotherapy, stereotactic body radiation therapy",
author = "Ryan Phillips and Piet Ost and Tran, {Phuoc T.}",
note = "Funding Information: P Ost is a senior clinical investigator of the Research Foundation – Flanders (FWO) (Belgium). PT Tran is funded by the Nesbitt-McMaster Foundation, American Lung Association (LCD-339465), Movember-PCF and the NIH (R01CA166348 & U01CA183031); PT Tran owns the patent “Compounds and Methods of Use in Ablative Radiotherapy. Patent filed 3/9/2012. PCT/US2012/028475. PCT/WO/2012/122471. Patent awarded 5/25/2015. Patient#: 9114158.” The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",
year = "2017",
month = oct,
doi = "10.2217/fon-2017-0337",
language = "English (US)",
volume = "13",
pages = "2121--2124",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "24",
}